Skip to main content

Effect of Prescribing Patterns of Renin–Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure

Abstract

Introduction

Use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) only, beta-blockers (BB) only, or both has been rarely compared in patients with heart failure (HF). We evaluated the prescribing patterns of ACEi/ARB and BB on prognosis in HF according to left ventricular function.

Methods

Study data were obtained from a national multicenter cohort that included patients hospitalized for HF. Patients were classified into four groups according to the prescription pattern at discharge: all ACEi/ARB and BB treatment group, only ACEi or ARB treatment group, only BB treatment group, and neither ACEi/ARB nor BB group.

Results

Use of both ACEi/ARB and BB had significantly lowest all-cause death rates among the four groups in all types of HF. Cox regression analysis showed that use of both drugs was independently associated with 51% reduced risk of all-cause death in patients with HF with preserved ejection fraction (HFpEF) and HF with mid-range ejection fraction (HFmrEF). Treatment with only ACEi/ARB also showed an independent association with a 52% reduction in this group. However, only BB treatment was not associated with reducing long-term mortality in patients with HFpEF and HFmrEF. In patients with HF with reduced ejection fraction, use of ACEi/ARB and/or BB revealed an independent association with a reduced risk of all-cause death regardless of prescribing patterns.

Conclusions

Prescribing patterns were diverse in HF and there was a difference in the degree of risk reduction in all-cause death. In particular, clinicians should consider ACEi/ARB first for patients with HFpEF and HFmrEF prior to BB.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics–2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–528.

    Article  Google Scholar 

  2. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.

    Article  Google Scholar 

  3. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61.

    Article  Google Scholar 

  4. Yaku H, Ozasa N, Morimoto T, et al. Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan—observations from the Prospective, Multicenter Kyoto Congestive Heart Failure (KCHF) Registry. Circ J. 2018;82:2811–9.

    Article  Google Scholar 

  5. Gilstrap LG, Stevenson LW, Small R, et al. Reasons for guideline nonadherence at heart failure discharge. J Am Heart Assoc. 2018;7:e008789.

    CAS  Article  Google Scholar 

  6. Teng TK, Tromp J, Tay WT, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018;6:e1008–18.

    Article  Google Scholar 

  7. Nagai T, Yoshikawa T, Saito Y, et al. Clinical characteristics, management, and outcomes of Japanese patients hospitalized for heart failure with preserved ejection fraction—a report from the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) Registry. Circ J. 2018;82:1534–45.

    Article  Google Scholar 

  8. Mahmood SS, Wang TJ. The epidemiology of congestive heart failure: the Framingham Heart Study perspective. Glob Heart. 2013;8:77–82.

    Article  Google Scholar 

  9. Kim HL, Kim MA, Choi DJ, et al. Gender difference in the prognostic value of N-terminal Pro-B type natriuretic peptide in patients with heart failure—a report from the Korean Heart Failure Registry (KorHF). Circ J. 2017;81:1329–36.

    CAS  Article  Google Scholar 

  10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.

    Google Scholar 

  11. Targher G, Dauriz M, Laroche C, et al. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:54–65.

    CAS  Article  Google Scholar 

  12. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–6.

    CAS  Article  Google Scholar 

  13. Cohn JN, Tognoni G, Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–75.

    CAS  Article  Google Scholar 

  14. SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.

    Article  Google Scholar 

  15. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–8.

    CAS  Article  Google Scholar 

  16. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194–9.

    Article  Google Scholar 

  17. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.

    CAS  Article  Google Scholar 

  18. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.

    CAS  Article  Google Scholar 

  19. Dauterman KW, Go AS, Rowell R, et al. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. J Card Fail. 2001;7:221–8.

    CAS  Article  Google Scholar 

  20. Ahmed A, Roseman JM, Duxbury AS, Allman RM, DeLong JF. Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. Am Heart J. 2002;144:365–72.

    Article  Google Scholar 

  21. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81.

    CAS  Article  Google Scholar 

  22. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67.

    CAS  Article  Google Scholar 

  23. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53:2150–8.

    Article  Google Scholar 

  24. Egido JJ, Gomez R, Romero SP, et al. Treatment with renin-angiotensin system inhibitors and prognosis of heart failure with preserved ejection fraction: a propensity-matched study in the community. Int J Clin Pract. 2019;73:e13317.

    Article  Google Scholar 

  25. Zheng SL, Chan FT, Nabeebaccus AA, et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2018;104:407–15.

    CAS  Article  Google Scholar 

  26. Kim SH, Yun SC, Park JJ, et al. Beta-blockers in patients with heart failure with preserved ejection fraction: results from the Korea acute heart failure (KorAHF) Registry. Korean Circ J. 2019;49:238–48.

    CAS  Article  Google Scholar 

  27. Park JJ, Choi HM, Hwang IC, et al. Myocardial strain for identification of beta-blocker responders in heart failure with preserved ejection fraction. J Am Soc Echocardiogr. 2019;32(1462–1469):e1468.

    Google Scholar 

  28. Savarese G, Orsini N, Hage C, et al. Utilizing NT-proBNP for eligibility and enrichment in trials in HFpEF, HFmrEF, and HFrEF. JACC Heart Fail. 2018;6:246–56.

    Article  Google Scholar 

Download references

Acknowledgments

We thank the participants of the study.

Funding

No funding or sponsorship was received for this study or publication of this article.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Hyun-Jin Kim, Sang-Ho Jo, Min-Ho Lee, Won-Woo Seo, Jin-Oh Choi and Kyu-Hyung Ryu have nothing to disclose.

Compliance with Ethics Guidelines

The study protocol complied with the Declaration of Helsinki 1964 and its later amendments and was reviewed and approved by the Institutional Review Board of Konkuk University Hospital (reference no. KUH 1010270) and each participating hospital. All patients provided written informed consent prior to participation in the study.

Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sang-Ho Jo.

Additional information

Digital Features

To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12623975.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 31 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kim, HJ., Jo, SH., Lee, MH. et al. Effect of Prescribing Patterns of Renin–Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure. Adv Ther 37, 3839–3849 (2020). https://doi.org/10.1007/s12325-020-01443-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-020-01443-6

Keywords

  • Angiotensin-converting enzyme inhibitor
  • Angiotensin receptor blockers
  • Beta-blocker
  • Ejection fraction
  • Heart failure